

# DUPLOSPRAY MIS Quick Reference Guide



## Instructions for Circulating Nurse – DUPLOSPRAY MIS Regulator

1



Position DUPLOSPRAY MIS System so the foot pedal is placed next to the surgeon's foot at time of application.

2



Attach black gas supply hose, located at back of regulator, to source of medical grade CO<sub>2</sub>.

3



Set CO<sub>2</sub> pressure between 51-100 psi.

4



Attach spray set sterile filters to regulator. Connect the blue vent line filter to the blue female luer and the clear gas line filter to the male luer on the regulator. *For additional reference, attach filters according to graphics on regulator faceplate.*

5




While depressing foot pedal, adjust gas flow rate to 2 liters per minute. Check gas flow by noting height of ball in flow gauge while stepping on foot pedal.

For Tech Support  
Call 1-877-TISSEEL

## Instructions for Scrub Nurse – DUPLOSPRAY MIS Applicator

1



Thread sterile replaceable tip onto applicator using tip alignment tool.

2



For Topical Use Only

Firmly attach the applicator to the TISSEEL syringe hubs.

3



For Topical Use Only

Fasten the pull strap to the TISSEEL syringe holder to assure the spray applicator is tightly secured.

4



Attach gas supply line, clear luer connector, to sterile applicator. Turn white locking collar counter clockwise to secure connection.

5



Attach patient vent line, red luer connector, to available female luer on trocar cannula vent valve. Ensure vent valve is fully open.

6



For Topical Use Only

Pass assembled TISSEEL and spray applicator to surgeon for spray application. Pass the end of the connection tube with the sterile filters to circulating nurse.

## Instructions for Surgeon – DUPLOSPRAY MIS System

1



Depress foot pedal to start gas flow prior to applying TISSEEL. Check gas flow gauge on regulator before inserting applicator into trocar. If flow level ball does not move when foot pedal is depressed, the applicator tip is occluded and should be replaced.

2



While activating foot switch, dispense TISSEEL through applicator tip by depressing DUPLOJECT plungers using slow, steady pressure. To stop spray delivery, release pressure on DUPLOJECT plungers while maintaining gas flow by holding down foot pedal for an additional 3-5 seconds to clear applicator tip.

### TIPS

- The patient vent line attached to the trocar cannula vent valve will only vent gas out when foot pedal is depressed. After connection to trocar cannula, ensure vent valve is fully open on trocar cannula prior to spray application.
- If tip becomes occluded during use, remove plugged tip by unscrewing it counterclockwise. Using a sterile cloth, wipe any clotted material off exposed tube ends. Screw on new tip and tighten with tip alignment tool.
- The twin-tube assembly can be easily separated as necessary to allow freedom of movement.

*Please see Indications and Important Risk Information on the back.*

Rx Only: For safe and proper use of the DUPLOSPRAY device, please refer to full device instructions for use included.



### **TISSEEL [Fibrin Sealant] Indications**

**Hemostasis:** TISSEEL is a fibrin sealant indicated as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of splenic injuries. TISSEEL is satisfactory for use in fully heparinized patients undergoing cardiopulmonary bypass

**Sealing:** TISSEEL is indicated as an adjunct to prevent leakage from colonic anastomoses following the reversal of temporary colostomies

### **Important Risk Information for TISSEEL**

**For Topical Use Only. Do not inject TISSEEL directly into the circulatory system. Intravascular application of TISSEEL may result in life-threatening thromboembolic events.** Caution should be exercised to minimize any risk of inadvertent intravascular application.

Do not use TISSEEL in individuals with a known hypersensitivity to aprotinin.

Do not use TISSEEL for the treatment of severe or brisk arterial bleeding. In these situations, TISSEEL will be washed away in the flow of blood before hemostasis can be attained.

Hypersensitivity or allergic/anaphylactoid reactions may occur with the use of TISSEEL. Symptoms associated with allergic reactions include: flush, urticaria, pruritus, nausea, drop in blood pressure, tachycardia or bradycardia, dyspnea, severe hypotension and anaphylactic shock. Such reactions may also occur in patients receiving TISSEEL for the first time.

Discontinue administration of TISSEEL in the event of hypersensitivity reactions.

Apply as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.

Air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer fibrin sealants. This event appears to be related to use of the spray device at higher than recommended pressures and in close proximity to the tissue surface.

The information presented here has been taken directly from the DUPLOSPRAY MIS Instructions For Use, PN 21281 Rev.A.

**For Tech Support Call 1-877-TISSEEL (1-877-847-7335)**

Baxter, Tisseel and Duploject are trademarks of Baxter international inc.

RM0500 06/2010

When applying fibrin sealants using a spray device, be sure to use the pressure within the pressure range recommended by the spray device manufacturer.

Exposure to solutions containing alcohol, iodine or heavy metals may cause TISSEEL to be denatured. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL.

The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries involving confined spaces have not been evaluated; its use in this setting is not FDA approved.

There have been rare reports of serious adverse events such as paralysis and other compressive complications possibly related to the use of fibrin sealant in combination with resorbable hemostatic agents.

TISSEEL is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer fibrin sealants. This event appears to be related to use of the spray device at higher than recommended pressures and in close proximity to the tissue surface.

Please see accompanying full Prescribing Information.

To achieve an optimal result, a spraying distance of 10-15 cm is recommended. In specific situations where spraying less than 10 cm is necessary, the gas pressure must be reduced appropriately.

***Baxter***

Baxter International Inc.  
One Baxter Parkway  
Deerfield, Illinois 60015

www.baxter.com